Spots Global Cancer Trial Database for Axitinib + Ipilimumab in Advanced Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Axitinib + Ipilimumab in Advanced Melanoma
Official Title: Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Study ID: NCT04996823
Conditions
Study Description
Brief Summary: The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.
Detailed Description: The safety and tolerability of the combination of ipilimumab and axitinib will be tested in advanced melanoma patients who are intolerable/refractory to anti-PD-1/PD-L1 therapy and have not previously received treatment with ipilimumab.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Contact Details
Name: Zeynep Eroglu, MD
Affiliation: Moffitt Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
